poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

Benzinga Newsdesk

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BHVN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development

    Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.

    BHVN